{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:21:01Z","timestamp":1794583261067,"version":"4.9.1"},"reference-count":122,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T033371\/1"],"award-info":[{"award-number":["MR\/T033371\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["IS-BRC-1215-20005"],"award-info":[{"award-number":["IS-BRC-1215-20005"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,3,21]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>Disease-modifying treatments for major neurocognitive disorders, including Alzheimer\u2019s disease, Parkinson\u2019s disease and other cognitive deficits, are among the main unmet needs in modern medicine. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in neurodegeneration through intermediate, aetiology-agnostic pathways, likely involving metabolic, inflammatory and several other relevant neurobiological processes. In vitro and animal studies have revealed promising signals of neuroprotection, with preliminary supportive evidence emerging from recent pharmacoepidemiological investigations and clinical trials. In this article, we comprehensively review studies that investigate the impact of GLP-1RAs on the various aetiologies of cognitive impairment and dementia syndromes. Focusing on evidence from human studies, we highlight how brain energy homeostasis, neurogenesis, synaptic functioning, neuroinflammation and other cellular stress responses, pathological protein aggregates, proteostasis, cerebrovascular system and blood-brain barrier dynamics may underlie GLP-1RA putative neuroprotective effects. We then report and appraise evidence from clinical studies, including observational investigations, clinical trials and pooled analyses. Finally, we discuss current challenges and perspectives ahead for research and clinical implementation of GLP-1RAs for the care of people with major neurocognitive disorders, including their individual brain penetrance potential, the need for response biomarkers and disease stage-based indications, their possible non-specific effects on brain health, their profile in terms of adverse events and other unwanted effects, the lack of long-term data for efficacy and safety, and issues surrounding cost and availability of treatment.<\/jats:p>","DOI":"10.1136\/jnnp-2024-335593","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T13:20:24Z","timestamp":1744291224000},"page":"870-883","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":40,"title":["Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders"],"prefix":"10.1136","volume":"96","clinical-trial-number":[{"clinical-trial-number":"nct01843075","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02953665","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Riccardo","family":"De Giorgi","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, UK"},{"name":"Oxford Health NHS Foundation Trust, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ghenciulescu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Yotter","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Taquet","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6813-8493","authenticated-orcid":false,"given":"Ivan","family":"Koychev","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, UK"},{"name":"Division of Brain Sciences, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2025081402151280000_96.9.870.1","unstructured":"Emmady PD , Schoo C , Disorder T . Major neurocognitive disorder (dementia). Treasure Island (FL): StatPearls, 2025."},{"key":"2025081402151280000_96.9.870.2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"2025081402151280000_96.9.870.3","doi-asserted-by":"crossref","unstructured":"Wang S , Jiang Y , Yang A , et al . The Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need. Aging Dis 2024. doi:10.14336\/AD.2024.1071","DOI":"10.14336\/AD.2024.1071"},{"key":"2025081402151280000_96.9.870.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01911-3","article-title":"Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2025081402151280000_96.9.870.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn4691"},{"key":"2025081402151280000_96.9.870.6","unstructured":"Collins L , Costello RA . Glucagon-like peptide-1 receptor agonists. Treasure Island (FL): StatPearls Publishing, 2024."},{"key":"2025081402151280000_96.9.870.7","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2025081402151280000_96.9.870.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.12.012"},{"key":"2025081402151280000_96.9.870.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01792-4"},{"key":"2025081402151280000_96.9.870.10","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: An in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"key":"2025081402151280000_96.9.870.11","unstructured":"National Institute on Aging . Exendin-4: from lizard to laboratory\u2026 and beyond. 2012. Available: https:\/\/www.nia.nih.gov\/news\/exendin-4-lizard-laboratory-and-beyond"},{"key":"2025081402151280000_96.9.870.12","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14426","article-title":"Exendin-4: A potential therapeutic strategy for Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"103","author":"Verma","year":"2024","journal-title":"Chem Biol Drug Des"},{"key":"2025081402151280000_96.9.870.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.adn4128"},{"key":"2025081402151280000_96.9.870.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.103021","article-title":"GLP-1 receptor agonists beyond diabetes management","volume":"78","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025081402151280000_96.9.870.15","unstructured":"U.S. Food and Drug Administration . FDA approves first medication for obstructive sleep apnea. U.S. Food and Drug Administration, 2024."},{"key":"2025081402151280000_96.9.870.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk5720"},{"key":"2025081402151280000_96.9.870.17","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-025-00390-x"},{"key":"2025081402151280000_96.9.870.18","first-page":"e650","article-title":"Genetic Variation in Targets of Antidiabetic Drugs and Alzheimer Disease Risk","volume":"99","author":"Tang","year":"2022","journal-title":"Neurology (ECronicon)"},{"key":"2025081402151280000_96.9.870.19","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e39157","article-title":"Genetic variability of incretin receptors affects the occurrence of neurodegenerative diseases and their characteristics","volume":"10","author":"Vogrinc","year":"2024","journal-title":"Heliyon"},{"key":"2025081402151280000_96.9.870.20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03355-2"},{"key":"2025081402151280000_96.9.870.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2018.08.012"},{"key":"2025081402151280000_96.9.870.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30231-3"},{"key":"2025081402151280000_96.9.870.23","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-024-03763-8","article-title":"The double life of glucose metabolism: brain health, glycemic homeostasis, and your patients with type 2 diabetes","volume":"22","author":"Schwartz","year":"2024","journal-title":"BMC Med"},{"key":"2025081402151280000_96.9.870.24","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2016.00108","article-title":"In Alzheimer\u2019s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial","volume":"8","author":"Gejl","year":"2016","journal-title":"Front Aging Neurosci"},{"key":"2025081402151280000_96.9.870.25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17718-y","article-title":"Blood-Brain Glucose Transfer in Alzheimer\u2019s disease: Effect of GLP-1 Analog Treatment","volume":"7","author":"Gejl","year":"2017","journal-title":"Sci Rep"},{"key":"2025081402151280000_96.9.870.26","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-230181"},{"key":"2025081402151280000_96.9.870.27","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol"},{"key":"2025081402151280000_96.9.870.28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5163"},{"key":"2025081402151280000_96.9.870.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104896"},{"key":"2025081402151280000_96.9.870.30","doi-asserted-by":"crossref","unstructured":"Edison P , Femminella GD , Ritchie CW , et al . Evaluation of liraglutide in the treatment of Alzheimer\u2019s disease. Alzheimers Dement 2021;17. doi:10.1002\/alz.057848","DOI":"10.1002\/alz.057848"},{"key":"2025081402151280000_96.9.870.31","doi-asserted-by":"publisher","DOI":"10.2174\/1567205016666190913155950"},{"key":"2025081402151280000_96.9.870.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.11.019"},{"key":"2025081402151280000_96.9.870.33","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2064"},{"key":"2025081402151280000_96.9.870.34","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020734","article-title":"Activation of Glucagon-Like Peptide-1 Receptor Ameliorates Cognitive Decline in Type 2 Diabetes Mellitus Through a Metabolism-Independent Pathway","volume":"10","author":"Li","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025081402151280000_96.9.870.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.03.010"},{"key":"2025081402151280000_96.9.870.36","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.99"},{"key":"2025081402151280000_96.9.870.37","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03355-3","article-title":"The redox language in neurodegenerative diseases: oxidative post-translational modifications by hydrogen peroxide","volume":"12","author":"Lee","year":"2021","journal-title":"Cell Death Dis"},{"key":"2025081402151280000_96.9.870.38","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.4103\/1673-5374.389626","article-title":"Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain","volume":"19","author":"Diz-Chaves","year":"2024","journal-title":"Neural Regen Res"},{"key":"2025081402151280000_96.9.870.39","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-024-01573-x","article-title":"Inflammatory proteins associated with Alzheimer\u2019s disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","volume":"16","author":"Koychev","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"2025081402151280000_96.9.870.40","first-page":"1219","article-title":"Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment","volume":"13","author":"Wang","year":"2020","journal-title":"Int J Clin Exp Med"},{"key":"2025081402151280000_96.9.870.41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311162","article-title":"Endothelial Function in Patients with Multiple Sclerosis: The Role of GLP-1 Agonists, Lipoprotein Subfractions, and Redox Balance","volume":"24","author":"Hardonova","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025081402151280000_96.9.870.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.12.032"},{"key":"2025081402151280000_96.9.870.43","doi-asserted-by":"crossref","DOI":"10.1186\/s12929-024-01090-x","article-title":"Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"31","author":"Hong","year":"2024","journal-title":"J Biomed Sci"},{"key":"2025081402151280000_96.9.870.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176936"},{"key":"2025081402151280000_96.9.870.45","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1205207","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer\u2019s disease models: a systematic review and meta-analysis of preclinical studies","volume":"14","author":"Kong","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025081402151280000_96.9.870.46","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102019","article-title":"The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP\/PS1 mice","volume":"89","author":"Forny Germano","year":"2024","journal-title":"Mol Metab"},{"key":"2025081402151280000_96.9.870.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113693"},{"key":"2025081402151280000_96.9.870.48","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-081401","article-title":"Protocol for a double-blind placebo-controlled randomised controlled trial assessing the impact of oral semaglutide in amyloid positivity (ISAP) in community dwelling UK adults","volume":"14","author":"Koychev","year":"2024","journal-title":"BMJ Open"},{"key":"2025081402151280000_96.9.870.49","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.188.Blood"},{"key":"2025081402151280000_96.9.870.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2024.09.003"},{"key":"2025081402151280000_96.9.870.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110688"},{"key":"2025081402151280000_96.9.870.52","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3233\/JAD-180808","article-title":"Association Between the Use of Antihyperglycemic Drugs and Dementia Risk: A Case-Control Study","volume":"66","author":"Bohlken","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2025081402151280000_96.9.870.53","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0259"},{"key":"2025081402151280000_96.9.870.54","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3233\/JAD-200618","article-title":"Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of \u223c130,000 Swedish Subjects over 14 Years","volume":"76","author":"Secnik","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"2025081402151280000_96.9.870.55","doi-asserted-by":"crossref","DOI":"10.1177\/1533317519899546","article-title":"Antidiabetic Drugs for the Risk of Alzheimer Disease in Patients With Type 2 DM Using FAERS","volume":"35","author":"Akimoto","year":"2020","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"2025081402151280000_96.9.870.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107295"},{"key":"2025081402151280000_96.9.870.57","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102726","article-title":"12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study","volume":"74","author":"De Giorgi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025081402151280000_96.9.870.58","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14313"},{"key":"2025081402151280000_96.9.870.59","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102689","article-title":"Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study","volume":"73","author":"Tang","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025081402151280000_96.9.870.60","doi-asserted-by":"crossref","DOI":"10.1002\/trc2.12139","article-title":"Association between exenatide use and incidence of Alzheimer\u2019s disease","volume":"7","author":"Zhou","year":"2021","journal-title":"Alzheimers Dement (N Y)"},{"key":"2025081402151280000_96.9.870.61","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40618-024-02466-4","article-title":"Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network\u202f: Author list","volume":"48","author":"Nassar","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"2025081402151280000_96.9.870.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113537"},{"key":"2025081402151280000_96.9.870.63","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15918"},{"key":"2025081402151280000_96.9.870.64","doi-asserted-by":"publisher","DOI":"10.7326\/M23-3220"},{"key":"2025081402151280000_96.9.870.65","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w"},{"key":"2025081402151280000_96.9.870.66","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3259-x","article-title":"Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer\u2019s disease: study protocol for a randomised controlled trial (ELAD study)","volume":"20","author":"Femminella","year":"2019","journal-title":"Trials"},{"key":"2025081402151280000_96.9.870.67","unstructured":"Shugart J . Liraglutide trial was negative four years ago, still negative today ALZFORUM2024. Available: https:\/\/www.alzforum.org\/news\/conference-coverage\/liraglutide-trial-was-negative-four-years-ago-still-negative-today [Accessed 27 Jan 2025]."},{"key":"2025081402151280000_96.9.870.68","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"2025081402151280000_96.9.870.69","doi-asserted-by":"crossref","DOI":"10.1002\/trc2.12268","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"key":"2025081402151280000_96.9.870.70","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18306"},{"key":"2025081402151280000_96.9.870.71","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-024-01645-y","article-title":"Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials","volume":"16","author":"Li","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"2025081402151280000_96.9.870.72","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3673","article-title":"Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: A systematic review and network meta-analysis","volume":"39","author":"Tian","year":"2023","journal-title":"Diabetes Metab Res Rev"},{"key":"2025081402151280000_96.9.870.73","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15331"},{"key":"2025081402151280000_96.9.870.74","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5448"},{"key":"2025081402151280000_96.9.870.75","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa262"},{"key":"2025081402151280000_96.9.870.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107132"},{"key":"2025081402151280000_96.9.870.77","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29992"},{"key":"2025081402151280000_96.9.870.78","doi-asserted-by":"publisher","DOI":"10.1172\/JCI68295"},{"key":"2025081402151280000_96.9.870.79","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson\u2019s disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"2025081402151280000_96.9.870.80","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3233\/JPD-181329","article-title":"What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson\u2019s Disease: A Post Hoc Analysis","volume":"8","author":"Athauda","year":"2018","journal-title":"J Parkinsons Dis"},{"key":"2025081402151280000_96.9.870.81","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"The Lancet"},{"key":"2025081402151280000_96.9.870.82","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312323"},{"key":"2025081402151280000_96.9.870.83","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00378-2"},{"key":"2025081402151280000_96.9.870.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107220"},{"key":"2025081402151280000_96.9.870.85","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30118-2"},{"key":"2025081402151280000_96.9.870.86","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001409"},{"key":"2025081402151280000_96.9.870.87","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12300-9"},{"key":"2025081402151280000_96.9.870.88","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S312527"},{"key":"2025081402151280000_96.9.870.89","first-page":"141","article-title":"12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus","volume":"10","author":"Perna","year":"2018","journal-title":"Clin Pharmacol"},{"key":"2025081402151280000_96.9.870.90","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-020-0535-5"},{"key":"2025081402151280000_96.9.870.91","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2584"},{"key":"2025081402151280000_96.9.870.92","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30173-3"},{"key":"2025081402151280000_96.9.870.93","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02320-7"},{"key":"2025081402151280000_96.9.870.94","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1047883","article-title":"Impact of glucagon-like peptide 1 analogs on cognitive function among patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"13","author":"Luan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025081402151280000_96.9.870.95","unstructured":"Weisenthal JA , Alloway T . GLP-1 drugs are coming, and they could change everything. 2023. Available: https:\/\/www.bloomberg.com\/news\/articles\/2023-08-18\/glp-1-drugs-are-coming-and-they-could-change-everything?embedded-checkout=true [Accessed 17 Jul 2024]."},{"key":"2025081402151280000_96.9.870.96","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00376-0"},{"key":"2025081402151280000_96.9.870.97","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.q1767","article-title":"How do drugs such as Ozempic work for weight loss\u2026 and everything else?","volume":"386","author":"Guenot","year":"2024","journal-title":"BMJ"},{"key":"2025081402151280000_96.9.870.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2016.10.001"},{"key":"2025081402151280000_96.9.870.99","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-021-00853-7"},{"key":"2025081402151280000_96.9.870.100","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2023.2292461","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"12","author":"Rhea","year":"2024","journal-title":"Tissue Barriers"},{"key":"2025081402151280000_96.9.870.101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114187"},{"key":"2025081402151280000_96.9.870.102","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.00555","article-title":"Brain Endothelial Cells Regulate Glucagon-Like Peptide 1 Entry Into the Brain via a Receptor-Mediated Process","volume":"11","author":"Fu","year":"2020","journal-title":"Front Physiol"},{"key":"2025081402151280000_96.9.870.103","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"2025081402151280000_96.9.870.104","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","article-title":"Central and peripheral GLP-1 systems independently suppress eating","volume":"3","author":"Brierley","year":"2021","journal-title":"Nat Metab"},{"key":"2025081402151280000_96.9.870.105","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15638"},{"key":"2025081402151280000_96.9.870.106","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13133729","article-title":"All GLP-1 Agonists Should, Theoretically, Cure Alzheimer\u2019s Dementia but Dulaglutide Might Be More Effective Than the Others","volume":"13","author":"Fessel","year":"2024","journal-title":"J Clin Med"},{"key":"2025081402151280000_96.9.870.107","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111698","article-title":"Acute changes in systemic glycemia gate access and action of GLP-1R agonist on brain structures controlling energy homeostasis","volume":"41","author":"Bakker","year":"2022","journal-title":"Cell Rep"},{"key":"2025081402151280000_96.9.870.108","doi-asserted-by":"publisher","DOI":"10.1177\/0004867418796955"},{"key":"2025081402151280000_96.9.870.109","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-024-10142-w"},{"key":"2025081402151280000_96.9.870.110","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2022.955258","article-title":"Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"14","author":"H\u00f6lscher","year":"2022","journal-title":"Front Synaptic Neurosci"},{"key":"2025081402151280000_96.9.870.111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"2025081402151280000_96.9.870.112","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2024.101100","article-title":"Recent achievements and future directions of anti-obesity medications","volume":"47","author":"Grandl","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2025081402151280000_96.9.870.113","doi-asserted-by":"publisher","DOI":"10.7326\/M23-2718"},{"key":"2025081402151280000_96.9.870.114","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48780-6"},{"key":"2025081402151280000_96.9.870.115","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01296-0"},{"key":"2025081402151280000_96.9.870.116","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01021-8"},{"key":"2025081402151280000_96.9.870.117","doi-asserted-by":"crossref","unstructured":"Chavda VP , Balar PC , Vaghela DA , et al . Unlocking longevity with GLP-1: A key to turn back the clock? Maturitas 2024;186. doi:10.1016\/j.maturitas.2024.108028","DOI":"10.1016\/j.maturitas.2024.108028"},{"key":"2025081402151280000_96.9.870.118","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2335215"},{"key":"2025081402151280000_96.9.870.119","doi-asserted-by":"publisher","DOI":"10.2337\/cd23-0023"},{"key":"2025081402151280000_96.9.870.120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269006","article-title":"Cost-effectiveness of the add-on exenatide to conventional treatment in patients with Parkinson\u2019s disease when considering the coexisting effects of diabetes mellitus","volume":"17","author":"Chen","year":"2022","journal-title":"PLoS One"},{"key":"2025081402151280000_96.9.870.121","doi-asserted-by":"crossref","unstructured":"H\u00f6lscher C . Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson\u2019s and Alzheimer\u2019s disease clinical trials: A revolution in the making? Neuropharmacology 2024;253. doi:10.1016\/j.neuropharm.2024.109952","DOI":"10.1016\/j.neuropharm.2024.109952"},{"key":"2025081402151280000_96.9.870.122","unstructured":"Ghenciulescu A . 2025. Available: https:\/\/BioRender.com\/g20w806"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-335593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T09:15:30Z","timestamp":1755162930000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-335593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":122,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,8,14]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/jnnp-2024-335593"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-335593","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}